New hope for tough myeloma: Two-Drug combo takes on relapsed cancer
NCT ID NCT06948084
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase II trial compares a new combination of daratumumab and teclistamab against standard treatments for high-risk multiple myeloma that has relapsed or not responded to therapy. About 80 adults will be randomly assigned to either the new combo or usual care. The goal is to see if the new approach can reduce cancer cells to undetectable levels more effectively.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
daratumumab and teclistamab
What this could lead to
If this works, it could offer a more effective treatment option for high-risk multiple myeloma patients whose cancer has returned or not responded to prior therapy.
What could go wrong
This is a small, early phase II trial with only 80 participants, so results may not apply broadly. The new combination may cause side effects or fail to outperform existing treatments.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for REFRACTORY MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.